In Vitro Activity of PNU-100766 (Linezolid), a New Oxazolidinone Antimicrobial, against Nocardia brasiliensis

AUTOR(ES)

Vera-Cabrera, Lucio

FONTE

American Society for Microbiology

RESUMO

The in vitro activity of a novel oxazolidinone, linezolid, was studied by comparing the activity of linezolid with those of amikacin, trimethoprim-sulfamethoxazole, and amoxicillin-clavulanic acid against 25 strains of Nocardia brasiliensis isolated from patients with mycetoma. All N. brasiliensis strains tested were sensitive to linezolid (MIC at which 90% of strains are inhibited [MIC90], 2 μg/ml; MIC50, 1 μg/ml). This antimicrobial might constitute a good alternative for treatment of actinomycetoma.

Documentos Relacionados

• Comparative In Vitro Activities and Postantibiotic Effects of the Oxazolidinone Compounds Eperezolid (PNU-100592) and Linezolid (PNU-100766) versus Vancomycin against Staphylococcus aureus, Coagulase-Negative Staphylococci, Enterococcus faecalis, and Enterococcus faecium
• In Vitro Activities of New Antimicrobials against Nocardia brasiliensis
• In vitro activities in new oxazolidinone antimicrobial agents against enterococci.
• In Vitro Activities of Linezolid against Multiple Nocardia Species
• In Vitro Activity of the New Oxazolidinone AZD2563 against Enterococci